Drosophila Cancer Models Identify Functional Differences between Ret Fusions.

Drosophila Cancer Models Identify Functional Differences between Ret Fusions.
复制标题

DOI:
10.1016/j.celrep.2016.08.019
复制
发表时间:
2016-09-13
期刊:
影响因子:
8.8
通讯作者:
Cagan RL
Cagan RL
中科院分区:
生物学1区
文献类型:
--
作者:
Levinson S;Cagan RL

文献摘要

参考文献

被引文献

相似文献

我们生成并比较了RET融合CCDC 6-RET和NCOA 4-RET的果蝇模型。两种RET融合体都指导细胞迁移、分层和经历EMT,并且当广泛表达时都导致致死性。在检查的所有表型中,NCOA 4-RET比CCDC 6-RET更严重,反映了它们对患者的影响。针对果蝇激酶组和癌症药物库的功能筛选发现,CCDC 6-RET和NCOA 4-RET通过不同的信号网络起作用,并显示出不同的药物敏感性。结合来自激酶组和药物筛选的数据,将WEE 1抑制剂AZD 1775加上多激酶抑制剂索拉非尼确定为特异性针对NCOA 4-RET的协同药物组合。我们的工作强调了识别和定制患者治疗的重要性,以其特定的RET融合亚型,并确定了一种多靶向治疗,可以证明对含有NCOA 4-RET融合的肿瘤有效。Levinson和Cagan研究了两种果蝇RET融合模型。他们发现N-末端有助于融合蛋白的整体功能,包括它们对治疗药物的反应。遗传和化学遗传筛选鉴定索拉非尼加AZD 1775的药物组合对NCOA 4-RET融合有效。
We generated and compared Drosophila models of RET fusions CCDC6-RET and NCOA4-RET. Both RET fusions directed cells to migrate, delaminate, and undergo EMT, and both resulted in lethality when broadly expressed. In all phenotypes examined NCOA4-RET was more severe than CCDC6-RET, mirroring their effects on patients. A functional screen against the Drosophila kinome and against a library of cancer drugs found that CCDC6-RET and NCOA4-RET acted through different signaling networks and displayed distinct drug sensitivities. Combining data from the kinome and drug screens identified the WEE1 inhibitor AZD1775 plus the multi-kinase inhibitor sorafenib as a synergistic drug combination that is specific for NCOA4-RET. Our work emphasizes the importance of identifying and tailoring a patient’s treatment to their specific RET fusion isoform and identifies a multi-targeted therapy that may prove effective against tumors containing the NCOA4-RET fusion. Levinson and Cagan examine two Drosophila RET-fusion models. They find that the N-terminus contributes to the overall function of fusion proteins, including their response to therapeutics. Genetic and chemical genetic screens identify a drug combination of sorafenib plus AZD1775 as effective against the NCOA4-RET fusion.
DOI: 10.1073/pnas.251194298
发表时间: 2001-11-20
影响因子: 11.1
作者:
Bennett, BL;Sasaki, DT;Anderson, DW
通讯作者: Anderson, DW
DOI: 10.1158/0008-5472.can-10-0460
发表时间: 2010-09-01
期刊: Cancer research
影响因子: 11.2
作者:
Iadevaia S;Lu Y;Morales FC;Mills GB;Ram PT
通讯作者: Ram PT
DOI: 10.1038/nm.2644
发表时间: 2012-02-12
期刊: Nature medicine
影响因子: 82.9
作者:
Kohno T;Ichikawa H;Totoki Y;Yasuda K;Hiramoto M;Nammo T;Sakamoto H;Tsuta K;Furuta K;Shimada Y;Iwakawa R;Ogiwara H;Oike T;Enari M;Schetter AJ;Okayama H;Haugen A;Skaug V;Chiku S;Yamanaka I;Arai Y;Watanabe S;Sekine I;Ogawa S;Harris CC;Tsuda H;Yoshida T;Yokota J;Shibata T
通讯作者: Shibata T
DOI: 10.1016/j.ecl.2008.02.006
发表时间: 2008-06-01
影响因子: 4.5
作者:
Castellone, Maria Domenica;Santoro, Massimo
通讯作者: Santoro, Massimo
DOI: 10.1016/0092-8674(90)90659-3
发表时间: 1990-02-23
期刊: CELL
影响因子: 64.5
作者:
GRIECO, M;SANTORO, M;VECCHIO, G
通讯作者: VECCHIO, G